Skip to main content

Table 1 Patient demographics and clinical parameters

From: Risk factors associated with cervical spine lesions in patients with rheumatoid arthritis: an observational study

Number of patients 185
Age (years) (IQR) 68 (62−74)
Sex (n) (male:female) 12:173
Age of RA onset (years) (IQR) 52 (43−64)
RA disease duration (years) (IQR) 11 (4.8−23)
CRP level (mg/dL) (IQR) 0.3 (0.1−1.1)
RF positive (n) 53 % (98/185)
MMP3 positive (n) 55 % (102/185)
DAS28-CRP (IQR) 2.3 (1.7−3.1)
RA stage (n) I: 10, II: 46, III: 40, IV: 89
Prednisolone (n) 49 % (90/185)
MTX (n) 63 % (116/185)
Biological agents (n) 30 % (56/185)
BMD of the lumbar spine (YAM) (IQR) 82 % (71−93)
BMD of the femoral neck (YAM) (IQR) 66 % (58−66)
Previous joint surgery (n) 22 % (40/185)
Administered biological agents
 Abatacept n = 17
 Etanercept n = 12
 Infliximab n = 10
 Tocilizumab n = 8
 Certolizumab pegol n = 5
 Adalimumab n = 3
 Golimumab n = 1
  1. BMD bone mineral density, CRP C-reactive protein, DAS28-CRP Disease Activity Score based on C-reactive protein, MTX methotrexate, MMP3 matrix metalloproteinase-3, RF rheumatoid factor, YAM young adult mean, IQR interquartile range